{"title":"Measuring the benefits of clinical decision support: return on investment.","authors":"A H Rosenstein","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In an effort to provide high quality care in a more cost-effective manner, health care providers have found it necessary to implement a series of decision support strategies designed to improve outcomes of care. While each of these strategies has measurable benefits, they each come along with additional costs. This article will describe a methodology for measuring the costs and direct and indirect benefits from decision support activities.</p>","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"28-43"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21784939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Enforcement spotlight shines on formularies: is your compliance program ready to refute kickback and false claims allegations?","authors":"M S Segall, H H Keuning","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"44-5"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21784940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Asthma: an analysis of high-cost patients.","authors":"D C Malone, K A Lawson, D H Smith","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To examine characteristics of asthma patients who accounted for 80 percent of national expenditures in 1994 dollars.</p><p><strong>Study design: </strong>Data were extracted from a comprehensive data source, the 1987 National Medical Expenditure Survey (NMES) of approximately 35,000 individuals.</p><p><strong>Patients and methods: </strong>Persons of interest were identified using any occurrence of the ICD-9 code 493 or subcategories. Population weighting factors were used to estimate the population in the United States who sought care for the treatment of asthma. Two groups were identified: a high-cost group, which accounted for 80 percent of the direct medical expenditures, and a low-cost group, which represented 20 percent of expenditures. All analyses were performed using SUDAAN software, which takes into account the complex sampling design used in NMES.</p><p><strong>Results: </strong>Individuals who rated their health as poor or fair were more likely to be in the high-cost group, as compared with those who rated their health as good or excellent (p < .0009). Persons who reported having Medicare, other government, or private insurance were more likely to be in the high-cost group as compared to those with Medicaid and self-pay (p = .01). A person was more likely to be in the high-cost group if he or she used four or more different medications to treat asthma (p < .0001).</p><p><strong>Conclusions: </strong>Persons with asthma are more likely to have greater medical expenditures if they use four or more medications and have deteriorated health status. Managed care organizations and public programs may find these characteristics useful in targeting asthma prevention and management programs.</p>","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"12-20"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21785092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Measuring the benefits of clinical decision support: return on investment.","authors":"A. Rosenstein","doi":"10.1097/00004010-199902420-00004","DOIUrl":"https://doi.org/10.1097/00004010-199902420-00004","url":null,"abstract":"In an effort to provide high quality care in a more cost-effective manner, health care providers have found it necessary to implement a series of decision support strategies designed to improve outcomes of care. While each of these strategies has measurable benefits, they each come along with additional costs. This article will describe a methodology for measuring the costs and direct and indirect benefits from decision support activities.","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1 1","pages":"28-43"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61795581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Findings of a three-year retrospective study to investigate prevalence and incidence of urinary incontinence and overactive bladder in a typical managed care setting.","authors":"P L Day","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study was conducted in a large, integrated HMO to determine the prevalence and incidence of urinary incontinence, identify a demographic profile of patients having the UI subgroup condition of overactive bladder, and collect data to create an economic cost of illness description regarding current diagnosis and treatment practices. Using ICD-9 and CPT codes and prescription drug claims data as markers for the disease, subjects were selected for inclusion in the study. Resource use cost data was collected from this cohort over a three-year period and analyzed for total and mean monthly costs.</p>","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21785091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"State regulation of pharmacy activities.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"53-65"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21784942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"One more time: please fire marginal employees.","authors":"D H Freed","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Managers should not second-guess themselves when contemplating termination of marginal employees, i.e., those with sustained poor attitudes or performances. Poor performers should not be allowed to disadvantage an otherwise successful team; management ought not to retain someone it cannot fully support; and termination may be interpersonally excruciating but is organizationally very invigorating. This article identifies ten reasons why marginal employees prevail and are not dealt with in organizations. Acknowledging these barriers is a valuable first step in moving from analysis to synthesis as concerns removing them in the future.</p>","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"46-52"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21784941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Promising pharmacological agents in the management of acute spinal cord injury.","authors":"E C Seidl","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The search for a pharmacologic treatment of acute spinal cord injury (SCI) dates back to the 1960s. It was not until 1990 that the pharmacologic agent methylprednisolone demonstrated improved outcomes in humans. Methylprednisolone has shown superiority to placebo in humans in two large, multicenter trials, and is the standard of care thus far. Other potentially useful agents include tirilazad, ganglioside (GM-1), and naloxone. Additional studies are needed for these agents to determine the optimal dose and timing of administration.</p>","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"20 1","pages":"21-7"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21784938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The impact of managed care on pharmacy practice.","authors":"K W Schafermeyer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>As prescription drug costs continue their rapid rise, managed care organizations (MCOs) are giving greater attention to containing drug costs. This article examines the impact of managed care on pharmacy practice and reviews types of reimbursement for managed care prescriptions. The author outlines cost-containment measures for MCOs and pharmacy benefit management companies, including the use of mail order pharmacies, electronic claims payment, establishment of formularies, therapeutic interchange and generic incentives, and other measures. Cost-containment steps for pharmacies focus on identifying dispensing costs, decreasing overhead, and reducing ingredient costs. The author recommends that pharmacists begin to demonstrate and establish the value of their cognitive services, especially in patient counseling, in order to obtain reimbursement for these services.</p>","PeriodicalId":80126,"journal":{"name":"Pharmacy practice management quarterly","volume":"19 4","pages":"99-116"},"PeriodicalIF":0.0,"publicationDate":"2000-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21636215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}